Avalo Therapeutics (AVTX) Capital Expenditures (QoQ) (2016 - 2023)
Avalo Therapeutics (AVTX) Capital Expenditures (QoQ) (2016 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 66.32% |
| Dec 31, 2022 | 269.64% |
| Sep 30, 2022 | -200.00% |
| Dec 31, 2021 | -150.53% |
| Mar 31, 2021 | -66.67% |
| Dec 31, 2019 | -99.96% |
| Sep 30, 2019 | -94.41% |
| Jun 30, 2019 | -45.20% |
| Mar 31, 2019 | -66.76% |
| Dec 31, 2018 | 1,176.28% |
| Sep 30, 2018 | 483.36% |
| Jun 30, 2018 | -65.11% |
| Mar 31, 2018 | 25.36% |
| Dec 31, 2017 | 147.78% |
| Mar 31, 2017 | -80.50% |
| Dec 31, 2016 | 42.35% |
| Sep 30, 2016 | -36.75% |
| Jun 30, 2016 | 15.30% |